TY - JOUR
T1 - Prevalence of obesity in people with and without type 1 diabetes across Belgium, Kuwait, and Mexico
T2 - an IMI2 SOPHIA study
AU - Al Ozairi, Ebaa
AU - Steenackers, Nele
AU - Pazmino, Sofia
AU - Alattar, Abdulnabi T.
AU - Al Kandari, Jumana
AU - Almeda-Valdes, Paloma
AU - Antonio-Villa, Neftali Eduardo
AU - Delfin, Carl
AU - Faradji, Raquel N.
AU - Garcia-Tuomola, A. Aili
AU - Irshad, Mohammad
AU - Longenecker, Joseph C.
AU - Rosen, Jonathan
AU - del Pozo, Carmen Hurtado
AU - Sparso, Thomas
AU - Lavens, Astrid
AU - Mathieu, Chantal
AU - van der Schueren, Bart
AU - le Roux, Carel W.
PY - 2024/11
Y1 - 2024/11
N2 - Background Individuals with type 1 diabetes (T1D) are traditionally perceived as lean, but recent evidence suggests an increasing trend of obesity. To provide global estimates, this study explored the prevalence of obesity among adults with and without T1D across three distinct global regions. Methods An observational, cross-sectional study was performed utilizing data from T1D registries and national health surveys to assess the prevalence of obesity (BMI >= 30 kg/m(2)) and the prevalence of overweight and obesity (BMI >= 25 kg/m(2)) across Belgium, Kuwait, and Mexico. Demographic and clinical characteristics of adults with and without T1D were assessed. Prevalence estimates were calculated through a binomial generalized linear mixed-effects model adjusting for age, sex, HbA1c, and survey year. As a sensitivity analysis, propensity score matching was performed for confounder adjustment of age and sex. Findings The study encompassed 3594 individuals with T1D (from 2003 to 2022) and 9898 without T1D (from 2014 to 2021). After model adjustment for confounders (age, sex, HbA1c% and data-collection year), individual obesity prevalence was lower in individuals with T1D in Kuwait and Mexico than among those without type 1 diabetes (Kuwait: 22% (CI: 18-26%) vs. 44% (CI: 41-48%); Mexico: 5% (CI: 3-7%) vs. 40% (CI: 38-42%)). In contrast, individuals with T1D in Belgium showed a more comparable proportions to those without T1D (12% (CI: 9-16%) vs. 16% (CI:11-22%)). Interpretation Our data reveal that obesity is prevalent among people with T1D. These findings underscore the need for targeted strategies in T1D care that address the growing concern of obesity.
AB - Background Individuals with type 1 diabetes (T1D) are traditionally perceived as lean, but recent evidence suggests an increasing trend of obesity. To provide global estimates, this study explored the prevalence of obesity among adults with and without T1D across three distinct global regions. Methods An observational, cross-sectional study was performed utilizing data from T1D registries and national health surveys to assess the prevalence of obesity (BMI >= 30 kg/m(2)) and the prevalence of overweight and obesity (BMI >= 25 kg/m(2)) across Belgium, Kuwait, and Mexico. Demographic and clinical characteristics of adults with and without T1D were assessed. Prevalence estimates were calculated through a binomial generalized linear mixed-effects model adjusting for age, sex, HbA1c, and survey year. As a sensitivity analysis, propensity score matching was performed for confounder adjustment of age and sex. Findings The study encompassed 3594 individuals with T1D (from 2003 to 2022) and 9898 without T1D (from 2014 to 2021). After model adjustment for confounders (age, sex, HbA1c% and data-collection year), individual obesity prevalence was lower in individuals with T1D in Kuwait and Mexico than among those without type 1 diabetes (Kuwait: 22% (CI: 18-26%) vs. 44% (CI: 41-48%); Mexico: 5% (CI: 3-7%) vs. 40% (CI: 38-42%)). In contrast, individuals with T1D in Belgium showed a more comparable proportions to those without T1D (12% (CI: 9-16%) vs. 16% (CI:11-22%)). Interpretation Our data reveal that obesity is prevalent among people with T1D. These findings underscore the need for targeted strategies in T1D care that address the growing concern of obesity.
KW - Obesity
KW - Type 1 diabetes
U2 - 10.1016/j.eclinm.2024.102869
DO - 10.1016/j.eclinm.2024.102869
M3 - Article
C2 - 39416388
SN - 2589-5370
VL - 77
SP - 102869
JO - EClinicalMedicine
JF - EClinicalMedicine
M1 - 102869
ER -